Litcius/Paper detail

Safety, Virologic Efficacy, and Pharmacokinetics of CT-P59, a Neutralizing Monoclonal Antibody Against SARS-CoV-2 Spike Receptor-Binding Protein: Two Randomized, Placebo-Controlled, Phase I Studies in Healthy Individuals and Patients With Mild SARS-CoV-2 Infection

Jin Yong Kim, Young Rock Jang, Jang Hee Hong, Jin Gyu Jung, Jae‐Hyeong Park, Adrian Streinu‐Cercel, Anca Streinu-Cercel, Oana Săndulescu, Sang Joon Lee, Sung Hyun Kim, Nahyun Jung, Seul Gi Lee, Jeong Eun Park, Min Kyung Kim, Da Bee Jeon, Yeo Jin Lee, Bum Soo Kim, Yeon Mi Lee, Kim Ys

2021Clinical Therapeutics47 citationsDOIOpen Access PDF

Topics & Concepts

MedicinePharmacokineticsPlaceboMonoclonal antibodyVirologySevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)Coronavirus disease 2019 (COVID-19)2019-20 coronavirus outbreakAntibodyPharmacologyInternal medicineImmunologyPathologyInfectious disease (medical specialty)Alternative medicineDiseaseOutbreakSARS-CoV-2 and COVID-19 ResearchCOVID-19 Clinical Research StudiesLong-Term Effects of COVID-19
Safety, Virologic Efficacy, and Pharmacokinetics of CT-P59, a Neutralizing Monoclonal Antibody Against SARS-CoV-2 Spike Receptor-Binding Protein: Two Randomized, Placebo-Controlled, Phase I Studies in Healthy Individuals and Patients With Mild SARS-CoV-2 Infection | Litcius